3/16
06:54 am
legn
GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth
Low
Report
GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth
3/16
06:26 am
legn
GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth
Low
Report
GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth
3/16
06:10 am
legn
GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth
Low
Report
GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth
3/16
03:05 am
legn
Genscript Biotech Corp (GNNSF) Full Year 2025 Earnings Call Highlights: Record Revenue Growth ... [Yahoo! Finance]
Low
Report
Genscript Biotech Corp (GNNSF) Full Year 2025 Earnings Call Highlights: Record Revenue Growth ... [Yahoo! Finance]
3/13
06:18 am
legn
Legend Biotech (LEGN) was upgraded by Truist Financial Corporation from "hold" to "strong-buy".
Low
Report
Legend Biotech (LEGN) was upgraded by Truist Financial Corporation from "hold" to "strong-buy".
3/11
09:58 pm
legn
Legend Biotech Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Legend Biotech Q4 Earnings Call Highlights [Yahoo! Finance]
3/11
01:40 pm
legn
Legend Biotech (LEGN) had its price target lowered by Morgan Stanley from $50.00 to $49.00. They now have an "overweight" rating on the stock.
Low
Report
Legend Biotech (LEGN) had its price target lowered by Morgan Stanley from $50.00 to $49.00. They now have an "overweight" rating on the stock.
3/11
10:18 am
legn
Legend Biotech (LEGN) had its price target lowered by Royal Bank Of Canada from $66.00 to $62.00. They now have an "outperform" rating on the stock.
Low
Report
Legend Biotech (LEGN) had its price target lowered by Royal Bank Of Canada from $66.00 to $62.00. They now have an "outperform" rating on the stock.
3/10
04:06 pm
legn
Legend Biotech (LEGN) was given a new $70.00 price target by Truist Financial Corporation.
Medium
Report
Legend Biotech (LEGN) was given a new $70.00 price target by Truist Financial Corporation.
3/10
03:12 pm
legn
Legend Biotech Corp (LEGN) Q4 2025 Earnings Call Highlights: Record Growth and Profitability ... [Yahoo! Finance]
Low
Report
Legend Biotech Corp (LEGN) Q4 2025 Earnings Call Highlights: Record Growth and Profitability ... [Yahoo! Finance]
3/10
03:02 pm
legn
Legend Biotech (LEGN) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
Low
Report
Legend Biotech (LEGN) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
3/10
01:02 pm
legn
Legend Biotech Corporation (LEGN) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Legend Biotech Corporation (LEGN) Q4 2025 Earnings Call Transcript [Seeking Alpha]
3/10
07:37 am
legn
Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights [Yahoo! Finance]
Low
Report
Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights [Yahoo! Finance]
3/10
07:15 am
legn
Legend Biotech Non-GAAP EPS of $0.01 misses by $0.18, revenue of $306.3M misses by $3.91M [Seeking Alpha]
Low
Report
Legend Biotech Non-GAAP EPS of $0.01 misses by $0.18, revenue of $306.3M misses by $3.91M [Seeking Alpha]
3/10
07:00 am
legn
Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights
Low
Report
Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights
3/9
05:31 pm
legn
Neuroendocrine Carcinoma Market Poised for Significant Growth During the Forecast Period (2026-2036) Driven by Rising Incidence and Advancements in Targeted Therapies | DelveInsight
Low
Report
Neuroendocrine Carcinoma Market Poised for Significant Growth During the Forecast Period (2026-2036) Driven by Rising Incidence and Advancements in Targeted Therapies | DelveInsight
3/9
05:31 pm
legn
Neuroendocrine Carcinoma Market Poised for Significant Growth During the Forecast Period (2026-2036) Driven by Rising Incidence and Advancements in Targeted Therapies | DelveInsight
Low
Report
Neuroendocrine Carcinoma Market Poised for Significant Growth During the Forecast Period (2026-2036) Driven by Rising Incidence and Advancements in Targeted Therapies | DelveInsight
2/26
08:45 am
legn
The International Myeloma Foundation Invites the Myeloma Community to Demonstrate the Spirit of #MoreThanMyeloma for 2026 Myeloma Action Month
Low
Report
The International Myeloma Foundation Invites the Myeloma Community to Demonstrate the Spirit of #MoreThanMyeloma for 2026 Myeloma Action Month
2/24
08:33 am
legn
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results [Yahoo! Finance]
Low
Report
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results [Yahoo! Finance]
2/24
08:00 am
legn
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results
Low
Report
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results
2/24
06:47 am
legn
Legend Biotech (NASDAQ:LEGN) was downgraded by analysts at Truist Financial Corporation from a "strong-buy" rating to a "hold" rating.
Low
Report
Legend Biotech (NASDAQ:LEGN) was downgraded by analysts at Truist Financial Corporation from a "strong-buy" rating to a "hold" rating.
2/23
01:05 pm
legn
Legend Biotech (NASDAQ:LEGN) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..
Medium
Report
Legend Biotech (NASDAQ:LEGN) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..
2/23
11:22 am
legn
Legend Biotech (LEGN) Valuation Check After Barclays Update And 2026 Profitability Targets [Yahoo! Finance]
Medium
Report
Legend Biotech (LEGN) Valuation Check After Barclays Update And 2026 Profitability Targets [Yahoo! Finance]
2/16
12:38 pm
legn
FDA Guidance on MRD Negativity Bodes Well for Legend Biotech (LEGN) [Yahoo! Finance]
Low
Report
FDA Guidance on MRD Negativity Bodes Well for Legend Biotech (LEGN) [Yahoo! Finance]
2/12
07:55 am
legn
Legend Biotech (NASDAQ:LEGN) was downgraded by analysts at Rothschild & Co Redburn from a "buy" rating to a "neutral" rating. They now have a $24.00 price target on the stock.
Low
Report
Legend Biotech (NASDAQ:LEGN) was downgraded by analysts at Rothschild & Co Redburn from a "buy" rating to a "neutral" rating. They now have a $24.00 price target on the stock.